Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003814 · ClinicalTrials.gov registry record · Phase 3

Eflornithine in Treating Patients With Bladder Cancer

A Phase 3 study of Bladder Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT00003814 is a Phase 3 study of Bladder Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 450 participants, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003814, a Phase 3 study of Bladder Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.

Conditions Studied

Bladder Cancer

Interventions

  • DRUG eflornithine

Study Locations (20)

California

  • Advanced Urology Medical Center - Anaheim
  • Citrus Valley Urological Medical Group - Glendora
  • University of California San Diego Cancer Center - La Jolla
  • San Diego Urology Center - La Mesa
  • South Coast Urological Medical Group - Laguna Hills
  • Foothill Urology Associates - Pasadena
  • San Bernadino Urological Associates - San Bernadino
  • DRC and Urological Physicians of San Diego - San Diego
  • UCSF Cancer Center and Cancer Research Institute - San Francisco

Florida

  • Tampa Bay Meical Research - Clearwater
  • University of Florida - Gainesville - Gainesville
  • Urology Health Center - New Port Richey
  • Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center - Sarasota
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Alabama

  • Urology Associates - Birmingham
  • Intouch Research - Huntsville

Georgia

  • Piedmont Urology PC - Atlanta
  • Georgia Urology - Atlanta

Connecticut

  • Urology Specialists, P.C. - Waterbury

District of Columbia

  • George Washington University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 1999-02
Est. Completion 2007-05
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003814

The ClinicalTrials.gov registry entry for NCT00003814 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which eflornithine is the first listed.

NCT00003814 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT00003814 about?

NCT00003814 is a clinical study titled "Eflornithine in Treating Patients With Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of efl...

What is the current status of trial NCT00003814?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 1999-02. Estimated completion is 2007-05.

What conditions does trial NCT00003814 study?

This clinical trial studies the following conditions: Bladder Cancer.

What interventions are being tested in trial NCT00003814?

The interventions under investigation include: eflornithine (DRUG).

Who is sponsoring clinical trial NCT00003814?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003814 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Bladder Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.